LPOXY initiates $28M Series A financing with 5 Horizons Ventures to fund pivotal trial
September 4, 2025 | Startland News Staff
PLATTE CITY, Mo. — Funding to secure the upcoming trial of a Missouri biopharmaceutical company’s solution for preventing a deadly gut infection could prove critical in the fight against a condition that claims 80 U.S. lives daily, said Dr. Larry Sutton.
LPOXY Therapeutics, which is developing a novel non-antibiotic therapy to prevent Clostridioides difficile infections (Cdiff), announced Wednesday it has signed a term sheet with 5Horizons Ventures, a life science venture capital firm focused on innovative healthcare solutions in support of a $28 million Series A financing.
Elevator pitch: LPOXY Therapeutics is transforming infection prevention with a first-in-class oral therapeutic aimed at preventing C. difficile colitis, a CDC-designated urgent public health threat that kills over 80 Americans every day. Our unique approach delivers oxygen directly to the gut, creating an environment hostile to C. difficile bacteria without using antibiotics.
The agreement facilitates the formation of an investment syndicate to fund LPOXY’s registrational STOP-Cdiff (SIDIPREV Trial On Prevention of C. difficile Infections) clinical trial.
“5 Horizons Ventures’ commitment marks a major milestone for LPOXY as we move toward launching our pivotal STOP-Cdiff trial,” said Sutton, CEO and co-founder of LPOXY, one of Startland News’ 10 Kansas City Startups to Watch in 2025. “SIDIPREV represents a novel approach to infection prevention that not only addresses a deadly unmet need but also aligns with hospital economics by reducing costly complications within fixed DRG payments.”
ICYMI: LPOXY Therapeutics punches back at gut infection (and a foe with a billion-year head start)
The upcoming trial is designed under the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs guidance and is intended to serve as the registrational study for SIDIPREV™, a therapy that aims to prevent life-threatening Cdiff in high-risk hospitalized patients. C. difficile is categorized by the CDC as an urgent public health threat that kills 80 Americans every day.
SIDIPREV is an orally administered, enteric-coated capsule that releases a metered dose of oxygen into the lower gastrointestinal tract, creating an environment hostile to anaerobic pathogens like C. difficile. Oxygen also suppresses toxin production and has mucosal anti-inflammatory effects.
As planned, STOP-Cdiff is a randomized, placebo-controlled superiority trial that will evaluate the efficacy and safety of SIDIPREV in approximately 500 hospitalized patients at elevated risk for Cdiff due to age and antibiotic exposure. LPOXY aims to launch the trial in Q3 2026 and file for approval in 2029.
“We’re impressed by the LPOXY team, their data, and their clear-eyed strategy for succeeding where many anti-infective programs have struggled,” said Paul Ferguson, partner and CFO of 5 Horizons Ventures. “SIDIPREV avoids the reimbursement and resistance-related hurdles that have plagued traditional antibiotics, making this a rare opportunity to unlock real economic value for patients, hospitals, and investors.”
LPOXY is actively building its investment syndicate and is in discussions with other institutional investors aligned with its late-stage clinical strategy.
2025 Startups to Watch
stats here
Related Posts on Startland News
Divide and conquer: Splitsy pulls $70K from crowdfunding, ‘extra bump’ toward launch
Splitsy is ready to cash in on its widespread consumer appeal, revealed Brad Starnes, announcing the close of the startup’s first crowdfunding campaign and what it might mean for its rapidly scaling future. “We’re sitting at about $130,000 in funding right now,” said Starnes, co-founder of Splitsy, noting a nearly $71,000 chunk of the startup’s…
KC Pioneers secure six-figure funding from up-and-coming investment firm backed by MySidewalk exec
“Investment” goes deeper than simply writing a check, Mark Josey said, noting Kansas City’s premier esports league plans on being intentional in raising its $2 million seed round. “When you’re looking for partners, investors and sponsors, it starts at the core with asking: Do they believe in our mission, vision and value? Do they have…
KC couple’s 15-year journey evolves into $4M 24-hour child care center in urban core
A multimillion-dollar expansion for KD Academy is expected to upgrade the early learning and child care center’s capacity from 95 to 430 students at its new headquarters on Prospect Avenue — a redevelopment boon for the east side corridor and the extension of a family’s long-running mission. “Our goal starting out was to create a…
Why KCK’s ‘dopest, 7-fingered, adopted, biracial business owner’ is serving kinship, coffee at his new cafe
When a new coffee shop in KCK’s Strawberry Hill neighborhood opens this fall, the space is expected to feature more than just specialty roasts — with financial literacy programming, community workouts and hip hop yoga sessions on the menu. “It’s never been about, ‘How can I make the most money the fastest?’” said TJ Roberts,…